Free Trial

Monte Rosa Therapeutics (GLUE) Insider Trading & Ownership

Monte Rosa Therapeutics logo
$7.67 -0.01 (-0.13%)
(As of 12/17/2024 ET)

Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
6.50%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
5
Amount Of
Insider Selling
(Last 12 Months)
$11.58 M
Get GLUE Insider Trade Alerts

Want to know when executives and insiders are buying or selling Monte Rosa Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

GLUE Insider Buying and Selling by Quarter

Monte Rosa Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/28/2024Versant Venture Capital Vi, L.Major ShareholderSell89,990$9.66$869,303.40  
9/20/2024Versant Venture Capital Vi, L.Major ShareholderSell1,132,566$6.53$7,395,655.98  
9/13/2024Versant Venture Capital Vi, L.Major ShareholderSell9,269$6.16$57,097.04  
9/11/2024Versant Venture Capital Vi, L.Major ShareholderSell541,897$6.00$3,251,382.00  
7/5/2024Edmund DunnInsiderSell1,610$3.83$6,166.30  
(Data available from 1/1/2013 forward)

GLUE Insider Trading Activity - Frequently Asked Questions

The list of insiders at Monte Rosa Therapeutics includes Edmund Dunn, and Versant Venture Capital Vi, L.. Learn more on insiders at GLUE.

6.50% of Monte Rosa Therapeutics stock is owned by insiders. Learn more on GLUE's insider holdings.

The following insiders have sold GLUE shares in the last 24 months: Edmund Dunn ($6,166.30), and Versant Venture Capital Vi, L. ($11,573,438.42).

Insiders have sold a total of 1,775,332 Monte Rosa Therapeutics shares in the last 24 months for a total of $11,579,604.72 sold.

Monte Rosa Therapeutics Key Executives

  • Dr. Markus Warmuth M.D. (Age 52)
    President, CEO & Director
    Compensation: $901.35k
  • Dr. Owen B. Wallace Ph.D. (Age 55)
    Chief Scientific Officer
    Compensation: $630.68k
  • Dr. Filip Janku M.D. (Age 49)
    Ph.D., Chief Medical Officer
    Compensation: $658.66k
  • Ms. Jennifer Champoux
    Chief People & Operations Officer
  • Dr. Sharon Townson Ph.D. (Age 49)
    Chief Technology Officer
  • Dr. John C. Castle Ph.D. (Age 52)
    Chief Data & Information Officer
  • Mr. Andrew Funderburk
    Senior VP and Head of IR & Strategic Finance
  • Mr. Philip Nickson J.D. (Age 45)
    Ph.D., General Counsel
  • Mr. Magnus Walter DPHIL
    Senior Vice President of Drug Discovery
  • Mr. Edmund Dunn (Age 58)
    Vice President & Corporate Controller
    1 recent trades


This page (NASDAQ:GLUE) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners